Ansucon Medical Completes New Round of RMB 100 Million Financing to Accelerate Commercialization of Host-Free Ultrasonic Surgical Device

VCBeat has learned that Ansukang Medical (Suzhou) Co., Ltd. (“Ansukang”), an innovative medical device manufacturer, recently announced the completion of a new round of financing amounting to hundreds of millions of yuan. This round was jointly invested by Taiping Innovation Investment Management Co., Ltd., Legend Capital, and SJ Jiacheng Investment Management Co. Ltd. The funds will be primarily used for the market promotion of its host-free ultrasonic scalpel, the development of its next-generation energy platform, and production capacity preparation.

Ansukang Medical is an innovative medical device company founded in Suzhou in 2020, built upon its proprietary core technology system. It is dedicated to providing Chinese healthcare professionals with superior and more user-friendly medical devices.

The company's founder, Zhang Tao, inHill-Rom, Johnson & Johnson, Chinese domestic medical device companiesWith extensive industry experience, leading the team in R&D ofWorld's First Split-Type Console-Free Ultrasonic ScalpelIt ranks first globally in related technological fields and is the only domestic brand in the ultrasonic scalpel sector to surpass foreign brands in highly integrated technology.

It is reported that the product obtained the certificate issued by the National Medical Products Administration in November 2022.Class III Medical Device Registration Certificateand officially launched sales in the second quarter of 2023. As of the first half of this year, volume-based procurementThe number of hospitals won in bids has exceeded 100.，The total number of hospitals admitted has exceeded 200.

Regarding this round of financing, Zhang Tao, founder of Ansukang Medical, stated“We sincerely appreciate the recognition and support from both new and existing shareholders for Ansukang. Since its launch, our console-free ultrasonic scalpel has rapidly gained initial market acceptance. This round of financing will help Ansukang accelerate the increase in market share of its console-free ultrasonic scalpel, speed up the R&D process for new product lines, and build a differentiated product portfolio. Our goal is to enable more healthcare professionals to use superior and more user-friendly tools, thereby reducing their workload in daily practice and allowing them to better serve patients.”

The ultrasonic scalpel market is one of the segments with the greatest potential for domestic substitution.

Against the backdrop of policies such as domestic substitution, volume-based procurement, and DRG-based payment, the market share of Chinese manufacturers is rapidly increasing. According to statistical analysis by Frost & Sullivan, China’s ultrasonic scalpel market is growing significantly faster than the global market, with its market size exceeding RMB 12.5 billion in 2021. From 2020 to 2025, the compound annual growth rate (CAGR) reached 24.9%, far surpassing the 10% growth rate of the global ultrasonic scalpel market. Driven by the confluence of multiple changes, the ultrasonic scalpel market is expected to continue expanding, presenting significant opportunities.

Notably, despite significant achievements in the localization of domestic ultrasonic scalpels, they still exhibit shortcomings compared to imported brands, such as main unit failures, unstable fluctuations in transducer frequency and impedance, and handpiece malfunctions.

The research and development (R&D) of ultrasonic surgical devices is a systematic engineering endeavor that requires substantial corporate investment, with a focus on the development of the main unit, transducers, and instrument shafts. Taking Johnson & Johnson as an example, the company places paramount importance on R&D details. To align with ultrasonic characteristics, it invests significant capital and dedicates several years to in-depth research and optimization across multiple aspects, including material selection, machining processes, and strengthening techniques for the instrument shafts.

These seemingly insignificant areas constitute a company’s core competitiveness and moat. Therefore, to take the lead in the ultrasonic scalpel market, Chinese manufacturers must not only achieve technological innovation and breakthroughs but also make substantial efforts in system integration, process optimization, and stable mass production.

Ansukang boasts a multidisciplinary team with expertise in R&D, manufacturing, regulatory affairs, and marketing, enabling it to comprehensively address the challenges of a complex and dynamic market environment.

The design of the host-free ultrasonic scalpel adopts the latest technology, eliminating the need for a separate console by integrating all functions into the handpiece. This breakthrough not only significantly reduces procurement costs for hospitals but also greatly simplifies operational workflows in clinical settings. More importantly, product stability has been substantially enhanced following mass production.

The next-generation host-free ultrasonic scalpel, designed and manufactured by Ansukang Medical, is an industry-iterative product.

The Next-Generation Console-Free Ultrasonic Scalpel

Compared with traditional ultrasonic scalpel designs (including products from foreign companies), Ansukang's ultrasonic scalpel adoptsHighly Integrated Design, integrating traditional components such as the ultrasonic generator, transducer, handpiece, and torque wrench into a single unit, thereby achieving a host-free ultrasonic scalpel system. This design not only significantly reduces the visible procurement costs for hospitals—eliminating the need for tendering and purchasing a separate ultrasonic scalpel console—but also saves on hidden costs across various stages, including storage, transportation, usage, management, maintenance, and waste disposal.

In consideration of optimizing the clinical experience, Ansukang has further addressed many of the issues associated with traditional ultrasonic scalpelsDetail Optimization, including sterile gear adjustment, optimized cable positioning, and a detachable design for the blade handle.

The gear-adjustment design enables the surgeon to independently control the entire system with one hand under sterile conditions, eliminating the need for assistance and thereby enhancing surgical efficiency. The optimized cable placement effectively prevents interference with ultrasonic scalpel manipulation and potential blade rebound, making procedures safer and more efficient. The handle features a detachable design (with disposable blades), which reduces the risk of cross-infection while significantly lowering the cost of ultrasonic scalpel consumables per procedure. The handle can be sterilized and reused, substantially reducing medical waste and offering greater environmental sustainability.

As the first domestically produced split-design, console-free ultrasonic scalpel, the product has drawn industry attention since its launch and is already in use at Beijing Chaoyang Hospital Affiliated to Capital Medical University, Henan Provincial People's Hospital, Tianjin Medical University Cancer Institute and Hospital, and other institutions.Widely Used in Clinical Practice at Leading Hospitals Across China。

Clinical feedback indicates that the device offers a moderate cutting speed and an excellent operational experience, with particularly outstanding hemostatic performance capable of sealing 5mm blood vessels. Meanwhile, optimized gear adjustments and cable design have significantly enhanced ease of use. The host-free design not only miniaturizes and intelligences the device but also effectively reduces the comprehensive per-procedure cost of ultrasonic scalpels for hospitals.

Ansukang’s host-free ultrasonic surgical system has undoubtedly injected new vitality into the highly homogenized ultrasonic scalpel market, serving as a landmark case of domestic brands evolving from import substitution to iterative innovation.

The host-free ultrasonic scalpel embodies the founding team’s innovative spirit and ability to execute. Innovation in high-value medical devices stems from deep insights into clinical needs, coupled with robust engineering design and mass production capabilities. Ansukang Medical undoubtedly holds significant advantages in terms of pricing, surgeons’ user experience details (such as single-handed power adjustment, tangle-free operation, and superior hemostatic performance), and the process for distributors to gain hospital access. As a latecomer, only products that achieve a “10x improvement” have the opportunity to surpass established competitors. This round of funding will further accelerate Ansukang Medical’s development.

The company will first intensify marketing efforts for its inaugural product line—the console-free ultrasonic scalpel—to increase its market share. Secondly, the company will move to diversify its product portfolio by initiating R&D on a second product line to meet the needs of more diverse medical scenarios. Finally, the company will proactively prepare production capacity to ensure efficient and stable manufacturing of high-quality console-free ultrasonic scalpels and other future product lines, while maintaining effective cost control, thereby laying a solid foundation for long-term corporate development. We have learned that the second product line will also differ from previous similar products, incorporating more innovative designs into its development. We eagerly anticipate the early launch of these subsequent products.

Regarding this round of financing, Mr. Zhou from Legend Capital stated“From a technological perspective, Ansukang has achieved significant innovative breakthroughs. Compared with traditional ultrasonic scalpel technologies, Ansukang has incorporated more innovative materials and new technologies into the research and development of its ultrasonic scalpels, substantially elevating the design standards of domestically produced ultrasonic scalpels. In addition to technological innovation, the founder of Ansukang possesses extensive industry experience. His career has been consistently focused on R&D, technology transfer, and all stages of production scaling—from small-batch to mass production—particularly accumulating profound expertise in lean manufacturing and the stability of large-scale volume production. This has provided him with a wealth of valuable experience in developing ultrasonic scalpel products. It is believed that the ultrasonic scalpel devices developed by Ansukang will become a disruptive innovation in the industry, holding the promise of driving generational advancement in the field of ultrasonic scalpels.”

Regarding this round of financing, Mr. Yan from Taiping Innovation stated“We have strong confidence in Ansukang’s innovation capabilities and market potential. The Ansukang team has not only successfully developed the world first host-free ultrasonic scalpel with a split design, but also demonstrated exceptional execution and forward-thinking vision in market promotion, production capacity preparation, and product line diversification. This innovative product is poised to break the monopoly of imported devices and bring new transformation to the healthcare industry. Moreover, its unique design philosophy and outstanding clinical performance have earned widespread market recognition. We believe that with the successful completion of this round of financing, Ansukang will further accelerate its market expansion and product innovation, delivering more high-quality and efficient medical device solutions to patients and healthcare professionals. Taiping Innovation looks forward to working hand in hand with Ansukang to jointly create a brighter future.”

Regarding this round of financing, Liu Haofei, Founding Partner of SJ Jiacheng, stated“With the gradual standardization of centralized procurement, cost containment measures, and single-use protocols for ultrasonic scalpels, domestically produced ultrasonic scalpels have entered a window period of rapid growth. From a clinical application perspective, Ansukang Medical focuses exclusively on the niche category of ultrasonic scalpels and currently boasts the lowest failure rate among domestic brands. This reflects the innovation behind its host-free ultrasonic scalpel product, as well as its strong engineering design capabilities demonstrated through factory mass production and competitive pricing. These advantages provide substantial incremental value to users, decision-makers, influencers, and purchasers in hospital clinical settings, which is expected to ultimately translate into rapid growth in the company’s revenue and profits. As a participant with independent intellectual property rights and a core focus on host-free technology, Ansukang Medical is well-positioned to gain a competitive edge against both domestic peers and leading overseas multinational corporations, offering promising prospects. We look forward to Ansukang Medical joining the first tier of the global energy-based surgical device market and competing on equal footing with multinational corporations (MNCs).”

Legend Capital, established in April 2001, is a leading professional investment firm in China specializing in early-stage venture capital and growth-stage private equity investment.

Over more than two decades of development, Legend Capital has adhered to internationally accepted standards, navigated the full management cycles of multiple funds, and delivered strong, sustainable fund performance. To date, it has invested in over 600 companies, with 113 achieving exit through initial public offerings (IPOs) on various global capital markets and nearly 100 exiting via mergers and acquisitions. Its portfolio includes leading enterprises such as iFlytek, Contemporary Amperex Technology Co., Limited (CATL), WuXi AppTec, and Pharmaron, as well as a substantial number of national-level “Specialized, Refined, Differential, and Innovative” Little Giants and Manufacturing Single Champions, thereby building a rich base of industrial resources.

Legend Capital has always remained true to its original mission: fostering enterprise innovation and growth, and driving industrial progress and social development through capital and management support. While delivering strong performance, it actively fulfills its social responsibilities and strives to achieve sustainable, high-quality development.

Taiping Innovation Investment Management Co., Ltd. (hereinafter referred to as “Taiping Innovation”) was established in December 2018 and is one of the first insurance-affiliated private equity fund management companies approved by the China Banking and Insurance Regulatory Commission (CBIRC). As the professional private equity investment platform under China Taiping Insurance Group, we leverage the professional advantages of insurance capital and fulfill our responsibilities as a central state-owned enterprise. We strategically invest in sectors such as healthcare, fintech, and advanced manufacturing, build a “Healthcare + Technology” ecosystem, actively support the rural revitalization strategy, synergize with our core insurance business, and strive to provide investors with stable investment returns.

Shengjing Jiacheng Venture Capital / Shengjing Wanglian was founded in 2007, with RMB 13 billion in assets under management. Its direct investments and fund-of-funds strategies have yielded 241 portfolio companies that have successfully gone public. Focusing on technological innovation sectors such as healthcare, new energy and new materials, semiconductors, and artificial intelligence, it is a well-known empowerment and acceleration platform for new economy enterprises in China.